Joint statement on EPA proposed rule and public availability of data (2019)
Authors:
H. Holden Thorp aff001; Magdalena Skipper aff002; Veronique Kiermer aff003; May Berenbaum aff004; Deborah Sweet aff005; Richard Horton aff006
Authors place of work:
Editor-in-Chief, family of journals, Washington, District of Columbia, United States of America
aff001; Editor-in-Chief, , London, United Kingdom
aff002; Executive Editor, () Journals, San Francisco, California, United States of America
aff003; Editor-in-Chief, , Washington, District of Columbia, United States of America
aff004; Vice President of Editorial, Cell Press, Cambridge, Massachusetts, United States of America
aff005; Editor-in-Chief, The Lancet, London, United Kingdom
aff006
Published in the journal:
Joint statement on EPA proposed rule and public availability of data (2019). PLoS Med 16(11): e32767. doi:10.1371/journal.pmed.1003014
Category:
Perspective
doi:
https://doi.org/10.1371/journal.pmed.1003014
Eighteen months after articulating our concerns [1] regarding the 2018 “Strengthening Transparency in Regulatory Science” rule proposed by the Environmental Protection Agency (EPA) [2], we have become more concerned in response to recent media coverage and a 13 November hearing on the role of science in decision-making at the EPA. These events suggest that the proposed rule is now moving toward implementation; whether it includes amendments sufficient to address the concerns raised by us and many others remains a question.
Our previous statement on the proposed rule, authored and published by the editors-in-chief of five major scientific journals in May 2018, reflected alarm that the proposal’s push for “transparency” would be used as a mechanism for suppressing the use of relevant scientific evidence in policy-making, including public health regulations. After the public comment period for the proposed rule closed, the EPA reported more than 590,000 comments from individuals and scientific, medical, and legal groups, many of which articulated similar concerns [3].
As leaders of peer-reviewed journals, we support open sharing of research data, but we also recognize the validity of scientific studies that, for confidentiality reasons, cannot indiscriminately share absolutely all data. Datasets featuring personal identifiers—including studies evaluating genomes of thousands of people to characterize medically relevant genetic variants—are but one example. Such data may be critical to developing new drugs or diagnostic tools but cannot be shared openly; even anonymized personal data can be subject to re-identification, and it has been a longstanding practice for agencies and journals to acknowledge the value of data privacy adjustments. The principles of careful data management, as they inform medicine, are just as applicable to data regarding environmental influences on public health. Discounting evidence from the decision-making process on the basis that some data is confidential runs counter to the EPA stated mission "to reduce environmental risks…based on the best available scientific information” [4].
We are also concerned about how the agency plans to consider options related to existing regulations. Even if a new standard is not applied retroactively, the standard could apply when a regulation is updated; thus, foundational science from years past—research on air quality and asthma, for example, or water quality and human health—could be deemed by the EPA to be insufficient for informing our most significant public health issues. That would be a catastrophe.
We urge the EPA to continue to adopt an approach that ensures the data used in decision-making are the best available, which will at times require consideration of peer-reviewed scientific data, not all of which may be open to all members of the public. The most relevant science, vetted through peer review, should inform public policy. Anything less will harm decision-making that claims to protect our health.
We hope that in the end, decisions that are made to inform the proposed EPA rule will rise above any form of politics, focusing on what’s best for our communities. We encourage anyone with concerns or opinions about this issue to express their views through relevant legislative channels. Whether submitting public comments to the EPA or communicating with lawmakers in Congress, it is important to emphasize that decision-making that affects us all should be informed by nothing less than the full suite of relevant science vetted through peer review.
Zdroje
1. Berg J, Campbell P, Kiermer V, Raikhel N, Sweet D. Joint statement on EPA proposed rule and public availability of data. Science. 2018; 360: 6388. 10.1126/science.aau0116.
2. U.S. Environmental Protection Agency, News Releases. EPA Administrator Pruitt proposes rule to strengthen science used In EPA regulations. 24 Apr 2018. Available from: www.epa.gov/newsreleases/epa-administrator-pruitt-proposes-rule-strengthen-science-used-epa-regulations.
3. U.S. Environmental Protection Agency, Science Advisor Programs. Strengthening transparency in regulatory science. 30 Apr 2018. Available from: www.epa.gov/osa/strengthening-transparency-regulatory-science.
4. U.S. Environmental Protection Agency. Our mission and what we do. 2018. Available from: www.epa.gov/aboutepa/our-mission-and-what-we-do.
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2019 Číslo 11
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Co dělat při intoleranci statinů?
- Pleiotropní účinky statinů na kardiovaskulární systém
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
Najčítanejšie v tomto čísle
- Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial
- Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records
- Oxygen systems to improve clinical care and outcomes for children and neonates: A stepped-wedge cluster-randomised trial in Nigeria
- Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis